



SECOND EDITION

Handbook of  
**Retinal Screening**  
**in Diabetes** *Diagnosis &  
Management*

**ROY TAYLOR & DEBORAH BATEY**

 **WILEY-BLACKWELL**



## Handbook of Retinal Screening in Diabetes

**Companion website**

This book is accompanied by a companion website:

**[www.wiley.com/go/taylor/retinalscreening](http://www.wiley.com/go/taylor/retinalscreening)**

The website features:

- PowerPoints of all figures from the book for downloading

# Handbook of Retinal Screening in Diabetes

Diagnosis and Management

**SECOND EDITION**

**Roy Taylor**

Professor of Medicine and Metabolism  
Institute of Cellular Medicine  
Newcastle University  
and Honorary Consultant Physician  
The Newcastle upon Tyne Hospitals NHS Foundation Trust  
Newcastle upon Tyne, UK

**Deborah Batey**

Quality Assurance Manager  
Newcastle, West Northumberland & Gateshead Retinal Screening Service  
The Newcastle upon Tyne Hospitals NHS Foundation Trust  
Newcastle upon Tyne, UK

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2012 © 2012, 2006 by John Wiley & Sons, Ltd

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

*Registered office:* John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial offices:* 9600 Garsington Road, Oxford, OX4 2DQ, UK  
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK  
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Taylor, Roy, 1952-

Handbook of retinal screening in diabetes / Roy Taylor, Deborah Batey. – 2nd ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-65849-9 (pbk. : alk. paper)

I. Batey, Deborah. II. Title.

[DNLM: 1. Diabetic Retinopathy--diagnosis--Handbooks. WK 39]

617.7'3--dc23

2011035460

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Set in 9.25/11.5 pt by Toppan Best-set Premedia Limited

# Contents

**Preface, ix**

**How to use this book, x**

**1 Type 1 Diabetes, 1**

- What causes type 1 diabetes?, 1
- Who gets type 1 diabetes?, 1
- How does it present?, 1
- Essentials of management, 2
- Complications, 7
- History, 8
- Further reading, 9

**2 Type 2 Diabetes, 10**

- What causes type 2 diabetes?, 10
- Who gets type 2 diabetes?, 10
- How does it present?, 11
- Management, 11
- Complications, 14
- History, 15
- Further reading, 17

**3 The Eye in Diabetes, 18**

- Structure of the normal eye, 18
- The retina, 21
- Diabetic retinopathy, 22
- Treatment of sight-threatening diabetic retinopathy, 26
- Further reading, 28

**4 The Need to Screen, 29**

- Is blindness preventable?, 29
- Can the progression of retinopathy be slowed?, 32
- Detecting asymptomatic retinopathy by screening, 32
- The five principles of retinal screening, 35
- Quality assurance, 36
- Retinal screening from the patient's perspective, 38
- Retinal screening from the screener's perspective, 39
- History of the development of retinal screening by photography-based systems in the UK, 40
- Further reading, 41

**5 Practical Screening, 42**

- Important first steps, 42
- Measuring visual acuity, 43

- Instilling eyedrops, 47
- Obtaining the image, 50
- Examining the image, 51
- Grading the image, 54
- Explaining the results of screening, 57
- Success of the screening visit, 59
- Organization of a district screening system, 59
- Links with your ophthalmologist, 62
- Further reading, 64

## **6 Normal Retinal Appearances, 65**

- Light reflection artefact (Figure 6.1), 66
- Light reflection artefact (Figure 6.2), 67
- Tortuous vessels (Figure 6.3), 68
- Tiger striping (Figure 6.4), 69
- Tiger striping (Figure 6.5), 70
- Myelinated fibres (Figure 6.6), 71
- Myopic crescent (Figure 6.7), 72
- Pigmented image (Figure 6.8), 73
- Asteroid hyalosis (Figure 6.9), 74
- Choroidal circulation (Figure 6.10), 75
- Eyelash artefact (Figure 6.11), 76

## **7 Background Retinopathy, 77**

- What is background retinopathy?, 77
- Lesions, 77
- Early background (Figure 7.1), 78
- Early background (Figure 7.2a), 79
- Early background (red-free version of Figure 7.2a) (Figure 7.2b), 80
- Early background (Figure 7.3), 81
- Early background (Figure 7.4), 82
- Early background (Figure 7.5), 83
- Early background (Figure 7.6), 84
- Moderate background (Figure 7.7a), 85
- Moderate background (red-free version of Figure 7.7a) (Figure 7.7b), 86

## **8 Maculopathy, 87**

- What is maculopathy?, 87
- Management of maculopathy, 88
- Exudates close to the fovea (Figure 8.1), 90
- Severe retinopathy close to the macula (Figure 8.2), 91
- Widespread exudates (Figure 8.3), 92
- Large plaque exudates (Figure 8.4), 93
- Linear exudates close to the fovea (Figure 8.5), 94
- Plaque exudates near the fovea (Figure 8.6), 95
- Circinate exudates within the arcades (Figure 8.7), 96
- Widespread exudates with circinates (Figure 8.8), 97
- Coalescent exudates in the macular region (Figure 8.9), 98



## **9 Severe Non-proliferative ('Pre-proliferative') Retinopathy, 99**

- Management of severe, non-proliferative retinopathy, 99
- Severe non-proliferative retinopathy (Figure 9.1), 100
- Severe non-proliferative retinopathy (Figure 9.2), 101
- Severe non-proliferative retinopathy (Figure 9.3), 102
- Severe non-proliferative (Figure 9.4), 103

## **10 Proliferative Retinopathy, 104**

- What is proliferative retinopathy?, 104
- Management of proliferative retinopathy, 104
- New vessels on the disc (Figure 10.1), 105
- Disc new vessels (Figure 10.2), 106
- Retinal new vessels (Figure 10.3a), 107
- Retinal new vessels – red-free image of Figure 10.3a (Figure 10.3b), 108
- New vessels on the retina (Figure 10.4), 109
- New vessels on the retina (Figure 10.5), 110
- New vessels on the retina (Figure 10.6), 111
- New vessels on the retina (Figure 10.7a), 112
- New vessels on the retina – red-free version of Figure 10.7a (Figure 10.7b), 113
- Old panretinal laser scars (Figure 10.8), 114
- Panretinal laser scars (Figure 10.9), 115
- Disc and retinal new vessels, with exudative maculopathy (Figure 10.10a), 116
- Disc and retinal new vessels, with exudative maculopathy (red-free version of Figure 10.10a) (Figure 10.10b), 117

## **11 Advanced Diabetic Eye Disease, 118**

- What is advanced?, 118
- Management of advanced diabetic eye disease, 118
- Early fibrosis (Figure 11.1), 119
- Fibrosis (Figure 11.2), 120
- Fibrovascular membrane (Figure 11.3), 121
- Preretinal haemorrhage (Figure 11.4), 122
- Preretinal haemorrhage (Figure 11.5), 123
- Severe exudative maculopathy (Figure 11.6), 124
- Preretinal haemorrhage and persisting new vessel formation (Figure 11.7), 125
- Preretinal haemorrhage (Figure 11.8), 126
- Fibrous band and heavy laser scars (Figure 11.9), 127

## **12 Non-diabetic Eye Disease, 128**

- What other diseases are common?, 128
- Other eye diseases, 128
- Drusen (Figure 12.1), 131
- Drusen (Figure 12.2), 132
- Atrophic chorioretinital scars (Figure 12.3), 133
- Old chorioretinitis (Figure 12.4), 134
- Papilloedema (Figure 12.5), 135

One year later – same eye as shown in Figure 12.5 (Figure 12.6), 136  
Papilloedema (Figure 12.7), 137  
Pigment epithelial hypertrophy (Figure 12.8), 138  
Cholesterol embolus (Figure 12.9), 139  
Branch retinal vein occlusion (Figure 12.10), 140  
Central retinal vein occlusion (Figure 12.11), 141  
Branch retinal artery occlusion (Figure 12.12), 142  
Glaucomatous disc (Figure 12.13), 143  
Macular hole (Figure 12.14), 144

### **13 Background Information, 145**

The UK Retinal Screening Diploma, 145  
Working towards the full Diploma, 146  
Driving and diabetes, 146  
Pregnancy, 147  
Insurance and diabetes, 147  
Employment and diabetes, 147  
Prescription charges, 148  
British Association of Retinal Screening, 148  
Diabetes UK, 148  
National Retinopathy Screening Systems, 149  
Patient leaflets, 149  
Ophthalmoscopy, 150

### **14 Self-assessment Questions, 152**

Chapter 1, 152  
Chapter 2, 153  
Chapter 3, 154  
Chapter 4, 154  
Chapter 5, 155  
Chapters 6–12, 157

### **15 Answers to Self-assessment Questions, 158**

Chapter 1, 158  
Chapter 2, 159  
Chapter 3, 160  
Chapter 4, 160  
Chapter 5, 161

### **16 Glossary of terms, 163**

### **Index, 167**

#### **Companion website**

This book is accompanied by a companion website:

[www.wiley.com/go/taylor/retinalscreening](http://www.wiley.com/go/taylor/retinalscreening)

The website features:

- PowerPoints of all figures from the book for downloading



## Preface to Second Edition

The second edition of this book benefits from the extensive feedback on the first edition received from retinal screeners and specialists in diabetes and ophthalmology. It retains the successful overall format of its predecessor and includes a range of new images. This edition has been co-authored by a retinal screener of many years experience. This extends the down-to-earth, practical slant of the first edition.

A simple and effective grading system is used to classify the images shown. Up-to-date information is provided on diagnosis and treatment of diabetic retinopathy. Additionally, new sections provide the information required to prepare for – and pass – the Diploma in Retinal Screening. This qualification is now necessary for all retinal screeners in the UK.

Using the approach demonstrated, the retinal screening team in Newcastle upon Tyne has recently been able to publish data showing that diabetes is no longer the commonest cause of preventable blindness in the working age population. The book reflects the expertise of the whole team, and we would particularly thank Mr Rajen Gupta, Consultant Ophthalmologist for his continuing expert input.

We hope that you will enjoy using this Handbook and the associated website. Most of all, we hope that it will contribute to best possible care for people with diabetes.

Roy Taylor and Deborah Batey  
January 2012

# How to Use This Book

The first five chapters of this book are intended to be self-contained – so that each can be read or not depending upon the needs of the reader. A summary of important information is provided as a fact file at the end of each of these chapters. Self-assessment questions for each chapter are given in Chapter 14.

When examining the images in Chapters 6–12 it is essential to use a bright light such as a desk lamp or be close to a bright reading lamp. Diffuse fluorescent lighting is particularly poor for seeing fine retinal details. However, to allow the viewing of images as they would be seen during screening – full size upon a screen – a website has been created for the use of readers of this book. It can be found at **[www.wiley.com/go/taylor/retinalscreening](http://www.wiley.com/go/taylor/retinalscreening)**. The images may be viewed either in colour or as red-free, and the images can be magnified as required. The descriptive text may be read to allow consideration of all the features.

The chapter on background information (Chapter 13) will introduce to people new to clinical diabetes or retinal screening the general knowledge that will benefit their patients.

# 1

## Type 1 Diabetes

---

### What causes type 1 diabetes?

Diabetes is a disorder in which blood glucose levels are high. In normal health, blood glucose levels are precisely controlled by the hormone insulin. This is made by the beta cells in the pancreas gland, an organ behind the stomach. Minute-to-minute control of insulin production by the beta cells normally keeps blood glucose levels constant. After a meal, the rate of insulin production rises sharply.

Type 1 diabetes is the result of destruction of the beta cells in the pancreas. This is most often caused by the body's defence mechanisms attacking the cells as though they were invaders (an 'autoimmune' process). The process of beta-cell destruction happens over a period of many months, but symptoms can start very suddenly once the number of functioning beta cells falls to a critical level.

---

### Who gets type 1 diabetes?

Type 1 diabetes used to be called juvenile-onset diabetes (and insulin-dependent diabetes mellitus). It can occur any time from early childhood into late adult life, but starts most commonly in early adolescence. The condition is slightly more likely to occur if family members have type 1 diabetes, but many people have no such family history.

Approximately 0.2% of children of school age have type 1 diabetes in the UK. In the population as a whole it affects around 0.3%.

---

### How does it present?

The main symptoms come on over a period of weeks and are:

- thirst
- passing large amounts of urine
- weight loss
- tiredness
- skin infections, especially thrush.

---

*Handbook of Retinal Screening in Diabetes: Diagnosis and Management*, Second Edition.  
Roy Taylor, Deborah Batey.

© 2012 John Wiley & Sons, Ltd. Published 2012 by John Wiley & Sons, Ltd.

There will be glucose (sugar) present in the urine. In addition, ketones are likely to be present in the urine. Ketones are the by-product of fat breakdown and are normal in trace amounts for anyone during fasting. However, excessive amounts of ketones are present in urine only when lack of insulin allows fat to break down excessively.

---

## Essentials of management

### Insulin


Insulin must be replaced to maintain life. As the insulin molecule is a peptide (a small protein), it would be broken down in the stomach if swallowed – just like any protein food. Insulin has to be injected into the fat layer under the skin. This may be done using a disposable syringe with insulin drawn from a vial, or by using a pen injector (Figure 1.1). It is usually advised that insulin be injected through the skin into the fatty tissue of the abdomen, the upper thighs or hips.

There are two basic types of insulin regimen. A combined injection of short-acting insulin and intermediate-acting insulin may be given before both breakfast and the evening meal (Figure 1.2). This has the advantage of simplicity, but the disadvantage that meals have to be eaten at fairly fixed times and in fairly fixed quantities.




**Figure 1.1** Insulin pens contain a 3 ml cartridge of insulin and are convenient to use because the required dose can rapidly be set and then injected. This avoids having to draw up a dose of insulin into a syringe from a vial


### Normal pattern in non-diabetic people



### Daily insulin levels on twice daily short- and longer-acting insulin



### Daily insulin levels on basal /bolus insulin regime



**Figure 1.2**

(a) Insulin levels normally increase sharply after meals, and fall back towards a low baseline afterwards; the black boxes show the meal times.

(b) This shows, in a diagrammatic form, what happens when a dose of short-acting insulin and a dose of longer-acting insulin are injected before both breakfast and the evening meal. This insulin regimen is simple, but does mean that meals have to be eaten at predictable times.

(c) This shows similar information when a basal (very-long-acting) insulin is injected before bed to provide a low background of insulin to mimic the normal situation. Doses of very short-acting insulin are given before meals, and there is flexibility in both the timing and the size of meals

**Table 1.1** Commonly used insulins and their time of action

Insulin <sup>a</sup>	Time of action	Use
Humalog Novorapid	0 min–2 hours <i>Very short</i>	As meal boluses (single doses)
Actrapid Humulin S	15 min–6 hours <i>Short</i>	1. As part of a twice daily short- and intermediate-acting insulin regimen 2. As meal boluses with evening long insulin
Humulin I Insulatard	1–14 hours <i>Intermediate</i>	1. As part of a twice daily short- and intermediate-acting insulin regimen 2. As overnight insulin (used with short-acting insulin to cover meals)
Lantus	1–24 hours <i>Long</i>	As basal insulin (used with boluses of very short-acting insulin to cover meals)

<sup>a</sup>The names in each box refer to similar insulins made by different manufacturers.

The second regimen tries to mimic the normal situation, with a low background of insulin being provided by a single daily injection of longer-acting insulin, together with the use of very short-acting insulin taken at a time when it is convenient to eat a meal, and in an amount corresponding to the size of that meal. Although this may involve three or more injections per day of very short-acting insulin, these can be given using a convenient pen device.

The insulin pump is an alternative approach to the second type of regimen. By having a continuous subcutaneous infusion of insulin with the possibility of giving doses before meals, these devices achieve similar control overall. Their usefulness has been hyped up too much, but they do suit some individuals very well.

The names of some of the commonly used insulins are listed in Table 1.1.

### Food


People with diabetes can eat normally, with a few modifications. Overall, the pattern of eating advised is merely that of a healthy lifestyle – not too much sugar, avoid fatty foods, and plenty of fruit and vegetables. Carbohydrate foods such as bread, pasta, potatoes and biscuits need to be considered in determining what dose of insulin is required. Since the 1930s carbohydrate has been ‘counted’ as 10 g exchanges. For example, an apple, a small potato or a digestive biscuit each can be counted as a 10 g exchange of carbohydrate. A person with diabetes is trained to assess how many carbohydrate exchanges would be in a meal. They will then inject meal-time insulin in a dose to cover this. For example, if an individual needed 1.0 units for each carbohydrate exchange then a meal consisting of 8 exchanges would require 8 units of insulin.



## Hypoglycaemia

This word merely means 'low blood glucose' and is usually shortened to 'hypo'. Hypos occur when the balance of injected insulin and food eaten is not correct. If, for example, only a small meal had been taken even though a dose of insulin appropriate for a larger meal had already been injected, then the insulin would have too great an effect upon blood glucose and the level will fall (Figure 1.3).

A hypo causes sweating, shakiness, a feeling of great hunger and eventually muddled thinking. If it is not treated by eating some sugary food, the muddled thinking will get worse and eventually the person will lose consciousness. There is a great risk that a person may be assumed to have drunk too much alcohol because of the uncoordinated movements and confusion.



**Figure 1.3** (a) In non-diabetic people, blood glucose levels rise after eating, but the rise is limited by the normal insulin response and smooth control is achieved whatever the size of the meal. In all the graphs the meal size is represented by the black boxes and the normal pre-meal range of glucose is shown by the shaded area. (b) In well-controlled type 1 diabetes the rise in blood glucose after eating is likely to be greater than normal, but, if the insulin dose (represented by the arrow) matches the meal size, control will be achieved. (c) If too great a dose of insulin were given, the rise after the meal would be smaller and blood glucose levels would fall below the normal range. Symptoms of a hypo would draw attention to the need for extra food, and blood glucose levels would tend to overshoot. (d) If only a small lunch were taken with a dose of insulin of usual size then blood glucose levels would rise little before the insulin caused a fall. Again, symptoms of a hypo would occur, extra food would be taken and blood glucose levels would overshoot

Especially after many years of type 1 diabetes, awareness of the early symptoms of hypos becomes blunted. There is then a risk of loss of consciousness without warning. The treatment of hypoglycaemia is administration of any sugary drink. A person who is hypoglycaemic may be uncooperative. Treatment from a doctor or paramedic would involve intravenous administration of glucose, or subcutaneous injection of glucagon. Glucagon is a hormone that has an opposite effect to that of insulin and causes the liver to produce glucose.

### **Ketoacidosis**

If a person with type 1 diabetes did not take insulin, glucose could not be used by the body and fat (the main alternative fuel) would be mobilized excessively. High levels of ketones would be present in the blood and urine. As ketones are weak acids, the blood becomes slightly acidic. Nausea and then vomiting occurs. Once vomiting starts the condition is likely to be fatal within 1–2 days unless treated.

Anyone with type 1 diabetes who is ill is advised to test their blood glucose frequently and also to test their urine for ketones. The insulin dose always needs to be increased during illness, even if no food is eaten (because the body becomes resistant to ordinary levels of insulin). It is vital that expert medical help is obtained. Hospital admission is necessary for established ketoacidosis.

### **Living with type 1 diabetes**


Few people who do not have type 1 diabetes actually appreciate the difficulty of living with a condition that requires attention every time the person wishes to eat or exercise.

To maintain the fine balance between blood glucose levels that are too high or too low requires detailed understanding of diabetes as well as hour-to-hour effort every single day. Adjusting insulin regimens to fit with work patterns, including shift work, is not always straightforward. In practice, individuals adopt habits that lead to average blood glucose levels, which reflect a compromise that they themselves can tolerate. These are often higher than might be ideal, but considerable empathy and insight into individual circumstances are required before it can be said that control 'must' be better. Most other people in the diabetes team do not need to take diabetes home with them.

During any minor illness the need for insulin rises and major adjustments are needed to keep control.

In order to hold a driving licence people with diabetes have to be able to recognize the early symptoms of hypoglycaemia, and have to obey the driving rules:

- Test blood glucose before driving
- Always keep glucose tablets or sweets in the car
- Plan longer journeys to ensure appropriate stops for snacks.



**Figure 1.4** To test blood glucose, a short needle is used to prick the finger and the drop of blood is placed on the test strip; the strip is connected to a small meter which gives a read-out of the result within seconds

### Blood glucose testing

It is only possible to 'know' one's own blood glucose level if it is either very high or very low. For this reason it is important for people with diabetes to be able to test their blood glucose level. By using a finger-pricking device, a tiny drop of blood can be obtained. This is placed on a disposable strip connected to a meter (Figure 1.4).

The level of glucose in blood is measured in millimoles per litre (mmol/l). The non-diabetic fasting range for blood glucose is 3.5–5.5 mmol/l. In type 1 diabetes blood glucose levels would ideally be between 4 and 7 mmol/l before meals, but in practice much higher numbers may be observed. For each individual, a target range will have been agreed. In very long-standing type 1 diabetes, blood glucose levels may vary unpredictably and it may be necessary to aim for higher numbers in order to avoid very frequent hypos.

---

### Complications

High blood glucose levels for many years can damage the smallest blood vessels – capillaries. The particular tissues that are most affected by this process are the retina, nerves and kidneys. These complications are known as 'microvascular' complications. The number of people with such complications increases as the duration of type 1 diabetes increases (see Figure 4.2).